Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor

OBJECTIVE: Limited studies have clearly demonstrated the effect of EGFR-TKI in the treatment of EGFR mutant NSCLC patients with underlying pulmonary disease, like pulmonary tuberculosis (PTB). Here, we conducted the study to evaluate the impact of PTB on survival of Chinese EGFR mutant lung adenocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yalin, Su, Ning, Zhou, Wei, Lei, An, Li, Xiang, Li, Weiwei, Huang, Zhan, Cen, Wenchang, Hu, Jinxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491869/
https://www.ncbi.nlm.nih.gov/pubmed/34621133
http://dx.doi.org/10.2147/CMAR.S326349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491869/
https://www.ncbi.nlm.nih.gov/pubmed/34621133
http://dx.doi.org/10.2147/CMAR.S326349

Ejemplares similares